Gilead Sciences, Inc. (GILD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1154797,
    "name": "Gilead Sciences, Inc.",
    "stock_name": "Gilead Sciences, Inc.",
    "full_name": "Gilead Sciences, Inc.",
    "name_url": "stocks-analysis/gilead-sciences-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "122.62",
    "chg": -1.29,
    "chgp": "-1.04%",
    "dir": -1,
    "prev_price": "123.91",
    "mcapval": "143,784.70",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US3755581036",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.5 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gilead-sciences-inc-1154797-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Gilead Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-overvalued-or-undervalued-3637434",
        "imagepath": "",
        "date": "2025-10-21 12:02:09",
        "description": "As of 17 October 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 7.30, and an EV to EBITDA of 11.39. In comparison, Amgen, Inc., a peer in the pharmaceuticals and biotechnology sector, has a higher P/E ratio of 19.10 and a lower EV to EBITDA of 13.08, suggesting that Gilead's valuation may not be justified relative to its competitors.\n\nGilead's recent stock performance has outpaced the S&P 500, with a year-to-date return of 32.95% compared to the index's 13.30%. However, the company's long-term returns over 10 years show stagnation, with both Gilead and the S&P 500 at 98.08%, which raises concerns about its growth potential despite recent gains. Overall, Gilead Sciences, Inc. is currently overvalue..."
      },
      {
        "title": "Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gilead-sciences-valuation-grade-changes-from-expensive-to-very-expensive-amid-strong-stock-performance-3640676",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/GileadSciencesI_valuationdot_3640676.png",
        "date": "2025-10-20 16:07:37",
        "description": "Gilead Sciences, Inc. has recently adjusted its valuation, with its current price reflecting a significant increase from the previous close. Over the past year, the company has achieved a strong return, outperforming the S&P 500. Key financial metrics indicate Gilead's solid market position and operational efficiency compared to its peers."
      },
      {
        "title": "Is Gilead Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-overvalued-or-undervalued-3634301",
        "imagepath": "",
        "date": "2025-10-20 12:19:58",
        "description": "As of 17 October 2025, Gilead Sciences, Inc. has moved from an expensive to a very expensive valuation grade, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 7.30, and an EV to EBITDA ratio of 11.39. In comparison, Amgen, Inc. has a higher P/E ratio of 19.10 and a lower EV to EBITDA of 13.08, suggesting that Gilead's valuation is not justified relative to its peers.\n\nDespite a strong return performance, with a year-to-date return of 32.95% compared to the S&P 500's 13.30%, the long-term outlook shows a concerning trend, as Gilead's 10-year return of 98.08% significantly lags behind the S&P 500's 227.77%. This disparity reinforces the notion that Gilead Sciences, Inc. is currently overvalued in the market...."
      },
      {
        "title": "Is Gilead Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-overvalued-or-undervalued-3631842",
        "imagepath": "",
        "date": "2025-10-19 11:57:35",
        "description": "As of 17 October 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued based on its P/E ratio of 15, which is lower than the peer average of approximately 15.53, and an EV to EBITDA ratio of 11.39 compared to Amgen, Inc.'s 13.08. Additionally, the PEG ratio stands at 0.81, suggesting that while growth may be priced attractively, the overall valuation metrics indicate a premium relative to its peers.\n\nIn terms of performance, Gilead has outperformed the S&P 500 over multiple periods, with a year-to-date return of 32.95% compared to the S&P 500's 13.30%, and a one-year return of 40.58% against 14.08%. This strong performance may reflect investor optimism, but the elevated valuation ratios suggest that the stock may not be a prudent investment at current levels...."
      },
      {
        "title": "Gilead Sciences, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gilead-sciences-inc-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-strong-performance-3559542",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/GileadSciencesI_technicaldot_3559542.png",
        "date": "2025-09-23 15:58:10",
        "description": "Gilead Sciences, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $112.49, with a notable annual return of 34.01%, surpassing the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and bearish trends across different timeframes."
      },
      {
        "title": "Is Gilead Sciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-technically-bullish-or-bearish-3558319",
        "imagepath": "",
        "date": "2025-09-23 11:18:44",
        "description": "As of 19 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is mildly bearish, while the monthly MACD indicates a bullish stance. The daily moving averages are mildly bullish, and the KST shows bullish signals for both weekly and monthly periods. The Bollinger Bands are sideways on the weekly but mildly bullish on the monthly. Overall, the technical indicators suggest a bullish stance, albeit with some caution due to the mixed signals on shorter time frames.\n\nIn terms of performance, Gilead has outperformed the S&P 500 year-to-date with a return of 21.78% compared to the S&P's 13.31%, and over the past year, it has returned 34.01% versus the S&P's 16.64%. However, over the 5-year period, Gilead has underperformed the S&P 500, returning 77.43% compared to 100.77%...."
      },
      {
        "title": "Is Gilead Sciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-technically-bullish-or-bearish-3552170",
        "imagepath": "",
        "date": "2025-09-22 18:05:06",
        "description": "As of 19 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by a bullish signal from the daily moving averages and a bullish KST on both weekly and monthly time frames. However, the weekly MACD and OBV are mildly bearish, indicating some short-term weakness. The stock has underperformed the S&P 500 over the past week and month, but it has significantly outperformed the benchmark year-to-date and over the past year. Overall, the strength of the bullish trend is tempered by mixed signals in the shorter time frames...."
      },
      {
        "title": "Is Gilead Sciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-technically-bullish-or-bearish-3544928",
        "imagepath": "",
        "date": "2025-09-20 18:59:28",
        "description": "As of 5 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD is bullish, suggesting mixed signals across time frames. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, supporting the overall bullish outlook. The KST is bullish in both weekly and monthly assessments, further reinforcing the positive sentiment. However, the weekly OBV is mildly bearish, which introduces some caution.\n\nIn terms of performance, Gilead has outperformed the S&P 500 year-to-date with a return of 23.01% compared to the S&P 500's 12.22%, and over the past year, it has returned 35.44% versus the S&P 500's 17.14%. Overall, the current technical stance is bullish, albeit with some mixed indicators suggesting caution in the short term...."
      },
      {
        "title": "Is Gilead Sciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gilead-sciences-inc-overvalued-or-undervalued-3541654",
        "imagepath": "",
        "date": "2025-09-20 17:31:56",
        "description": "As of 7 July 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current pricing relative to its fundamentals. The company appears overvalued, particularly given its P/E ratio of 15, which is lower than the peer average of approximately 15.53 for companies like Amgen, Inc. with a P/E of 19.10. Additionally, Gilead's EV to EBITDA stands at 11.39, while its peer average is 13.08, further highlighting the disparity in valuation metrics.\n\nIn terms of profitability, Gilead boasts a robust ROE of 49.06% and a PEG ratio of 0.81, suggesting that while the company is generating strong returns, its growth may not justify its high valuation. The recent stock performance shows that Gilead's returns have outpaced the S&P 500 year-to-date and over one year, with a YTD return of 23.01% compared to 12.22% for the index, but its longe..."
      }
    ],
    "total": 14,
    "sid": "1154797",
    "stock_news_url": "https://www.marketsmojo.com/news/gilead-sciences-inc-1154797"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Gilead Sciences, Inc. overvalued or undervalued?

2025-10-21 12:02:09

As of 17 October 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 7.30, and an EV to EBITDA of 11.39. In comparison, Amgen, Inc., a peer in the pharmaceuticals and biotechnology sector, has a higher P/E ratio of 19.10 and a lower EV to EBITDA of 13.08, suggesting that Gilead's valuation may not be justified relative to its competitors. Gilead's recent stock performance has outpaced the S&P 500, with a year-to-date return of 32.95% compared to the index's 13.30%. However, the company's long-term returns over 10 years show stagnation, with both Gilead and the S&P 500 at 98.08%, which raises concerns about its growth potential despite recent gains. Overall, Gilead Sciences, Inc. is currently overvalue...

Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics

2025-10-20 16:07:37

Gilead Sciences, Inc. has recently adjusted its valuation, with its current price reflecting a significant increase from the previous close. Over the past year, the company has achieved a strong return, outperforming the S&P 500. Key financial metrics indicate Gilead's solid market position and operational efficiency compared to its peers.

Is Gilead Sciences, Inc. overvalued or undervalued?

2025-10-20 12:19:58

As of 17 October 2025, Gilead Sciences, Inc. has moved from an expensive to a very expensive valuation grade, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 7.30, and an EV to EBITDA ratio of 11.39. In comparison, Amgen, Inc. has a higher P/E ratio of 19.10 and a lower EV to EBITDA of 13.08, suggesting that Gilead's valuation is not justified relative to its peers. Despite a strong return performance, with a year-to-date return of 32.95% compared to the S&P 500's 13.30%, the long-term outlook shows a concerning trend, as Gilead's 10-year return of 98.08% significantly lags behind the S&P 500's 227.77%. This disparity reinforces the notion that Gilead Sciences, Inc. is currently overvalued in the market....

Is Gilead Sciences, Inc. overvalued or undervalued?

2025-10-19 11:57:35

As of 17 October 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued based on its P/E ratio of 15, which is lower than the peer average of approximately 15.53, and an EV to EBITDA ratio of 11.39 compared to Amgen, Inc.'s 13.08. Additionally, the PEG ratio stands at 0.81, suggesting that while growth may be priced attractively, the overall valuation metrics indicate a premium relative to its peers. In terms of performance, Gilead has outperformed the S&P 500 over multiple periods, with a year-to-date return of 32.95% compared to the S&P 500's 13.30%, and a one-year return of 40.58% against 14.08%. This strong performance may reflect investor optimism, but the elevated valuation ratios suggest that the stock may not be a prudent investment at current levels....

Gilead Sciences, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-09-23 15:58:10

Gilead Sciences, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $112.49, with a notable annual return of 34.01%, surpassing the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and bearish trends across different timeframes.

Is Gilead Sciences, Inc. technically bullish or bearish?

2025-09-23 11:18:44

As of 19 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is mildly bearish, while the monthly MACD indicates a bullish stance. The daily moving averages are mildly bullish, and the KST shows bullish signals for both weekly and monthly periods. The Bollinger Bands are sideways on the weekly but mildly bullish on the monthly. Overall, the technical indicators suggest a bullish stance, albeit with some caution due to the mixed signals on shorter time frames. In terms of performance, Gilead has outperformed the S&P 500 year-to-date with a return of 21.78% compared to the S&P's 13.31%, and over the past year, it has returned 34.01% versus the S&P's 16.64%. However, over the 5-year period, Gilead has underperformed the S&P 500, returning 77.43% compared to 100.77%....

Is Gilead Sciences, Inc. technically bullish or bearish?

2025-09-22 18:05:06

As of 19 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by a bullish signal from the daily moving averages and a bullish KST on both weekly and monthly time frames. However, the weekly MACD and OBV are mildly bearish, indicating some short-term weakness. The stock has underperformed the S&P 500 over the past week and month, but it has significantly outperformed the benchmark year-to-date and over the past year. Overall, the strength of the bullish trend is tempered by mixed signals in the shorter time frames....

Is Gilead Sciences, Inc. technically bullish or bearish?

2025-09-20 18:59:28

As of 5 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD is bullish, suggesting mixed signals across time frames. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, supporting the overall bullish outlook. The KST is bullish in both weekly and monthly assessments, further reinforcing the positive sentiment. However, the weekly OBV is mildly bearish, which introduces some caution. In terms of performance, Gilead has outperformed the S&P 500 year-to-date with a return of 23.01% compared to the S&P 500's 12.22%, and over the past year, it has returned 35.44% versus the S&P 500's 17.14%. Overall, the current technical stance is bullish, albeit with some mixed indicators suggesting caution in the short term....

Is Gilead Sciences, Inc. overvalued or undervalued?

2025-09-20 17:31:56

As of 7 July 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current pricing relative to its fundamentals. The company appears overvalued, particularly given its P/E ratio of 15, which is lower than the peer average of approximately 15.53 for companies like Amgen, Inc. with a P/E of 19.10. Additionally, Gilead's EV to EBITDA stands at 11.39, while its peer average is 13.08, further highlighting the disparity in valuation metrics. In terms of profitability, Gilead boasts a robust ROE of 49.06% and a PEG ratio of 0.81, suggesting that while the company is generating strong returns, its growth may not justify its high valuation. The recent stock performance shows that Gilead's returns have outpaced the S&P 500 year-to-date and over one year, with a YTD return of 23.01% compared to 12.22% for the index, but its longe...

View All News